Parcoten (Acetaminophen,Codeine)

Quick links to important sections

Parcoten (Acetaminophen,Codeine)

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Parcoten (Acetaminophen,Codeine)

Property Description
Active Ingredients Acetaminophen (Paracetamol) and Codeine phosphate
Form Tablet (Oral preparation)
Pharmacological Class Compound Analgesic / Narcotic Analgesic Combination
Common Use Relief of moderate to severe pain
Origin Synthetic (Acetaminophen) / Semi-synthetic (Codeine)

What Type of Medicine is Parcoten (Acetaminophen, Codeine)?

Parcoten is a prescription-only medication classified as a Compound Analgesic, primarily used for the systemic management of moderate to severe pain. It is a fixed-dose combination product, meaning it contains two distinct active ingredients to achieve a combined therapeutic effect, and it is most commonly supplied as a tablet for oral administration.

This formulation is clinically recognized for providing effective pain management when single-agent analgesics, such as over-the-counter Acetaminophen, prove insufficient. The combination places the drug in the Narcotic Analgesic Combinations class, a category used when pain requires a multi-modal approach. The combination is one of the most frequently prescribed compound analgesics worldwide, often appearing under generic names like Co-codamol or analogue brands like Tylenol with Codeine in different markets, demonstrating its widespread acceptance in moderate pain protocols.

Composition and Origin: Acetaminophen, Codeine, and Their Purpose

Parcoten's composition relies on the distinct pharmacological roles of its two active ingredients: the non-opioid analgesic Acetaminophen (Paracetamol) and the weak opioid analgesic Codeine phosphate. Acetaminophen is a synthetic compound, while Codeine is derived from opium, classifying it as a semi-synthetic weak opioid.

The dual formulation is utilized because Acetaminophen helps reduce the creation of pain signals and assists in managing fever, while Codeine works centrally on the nervous system to modify the perception of pain. The combined effect allows for potentiated analgesia, meaning the efficacy is greater than if the components were administered separately. This systemic approach is a key differentiating factor, making the combination suitable for managing persistent or intense discomfort that requires both a peripheral and central level of intervention.

Regulatory References

  1. NIH/MedlinePlus

What side effects are possible with Parcoten (Acetaminophen,Codeine)?

Possible side effects and safety information

The safety profile of Parcoten, an Acetaminophen and Codeine combination product, is formally documented by regulatory authorities, classifying potential adverse reactions by frequency and affected organ system. This information is derived from clinical data and post-marketing surveillance, distinguishing between common, expected events and rare, serious concerns.


Frequency-Classified Adverse Reactions

The most frequently documented side effects relate to the central nervous system and gastrointestinal tract:

  • Very Common (occurs in ge 1 in 10 patients): Drowsiness, Nausea, and Vomiting.
  • Common (occurs in ge 1 in 100 to < 1 in 10 patients): Constipation, Dizziness, Headache, and Sweating.
  • Rare effects include Hepatic Dysfunction and certain blood disorders such as Thrombocytopenia.

Serious Adverse Reactions and Safety Constraints

The regulatory label highlights critical safety concerns. The risk of Severe Hepatic Failure is associated with the Acetaminophen component, particularly if the maximum daily dose is exceeded. Respiratory Depression is noted as a serious, dose-related risk due to the Codeine component.

Official safety constraints address specific patient groups and duration of use:

  • Older Adults may experience increased sensitivity to CNS effects, including a heightened risk of respiratory depression.
  • Nursing Mothers and Pediatric Patients (under 12 years of age) have specific documented risks, primarily related to Codeine metabolism, leading to restrictions on use in these populations.
  • The risks of developing physical dependence and tolerance are explicitly associated with long-term exposure to the medication.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of this medication involves acute, potentially fatal toxicities related to both active components. Immediate medical attention is required upon any suspected overdose, regardless of whether symptoms are currently present.

Clinical manifestations of overdose can be separated by component. Codeine overdosage may lead to central nervous system depression, including somnolence, miosis (pinpoint pupils), and severe respiratory depression that can progress to apnea or circulatory collapse. Acetaminophen overdosage, conversely, may initially present with non-specific symptoms such as nausea, vomiting, and malaise, but the critical risk is delayed, leading to progressive hepatic necrosis and potentially fatal acute hepatic failure.

The regulatory profile mandates an urgent hospital evaluation for all suspected cases because severe liver damage can occur even when initial symptoms are absent. Management involves the use of specific, regulator-documented antidotes: Naloxone for opioid-induced respiratory depression and N-acetylcysteine for Acetaminophen toxicity. Extended observation, often for a minimum of 24 hours, and serial laboratory monitoring of liver function are required procedures to assess the full extent of the toxicity. Specific population considerations include an increased risk of severe respiratory depression in pediatric ultra-rapid metabolizers of Codeine.

Therapeutic Uses of Parcoten (Acetaminophen,Codeine)

What Parcoten (Acetaminophen, Codeine) Treats: Main Uses and Benefits

The primary role of Parcoten is applied to provide additional symptomatic support for physical discomfort in situations where single-ingredient pain relievers are insufficient. It is used across therapeutic domains where short-term symptomatic assistance is needed.

The medication is relevant in clinical settings marked by heightened patient distress and is considered appropriate for addressing symptoms related to physical discomfort. It is utilized for the relief of pain in contexts where a multi-modal approach to symptomatic support is required.


Key Therapeutic Applications

Parcoten is commonly used to address pronounced symptoms that are classified as moderate to moderately severe, such as intense headaches, toothaches, neuralgia, discomfort following dental or minor surgical procedures, musculoskeletal pain, and intense episodic pain like primary dysmenorrhea. This helps address symptom clusters that may become intense or disruptive.

“This medication is typically used to help manage pain when symptoms create noticeable interference with daily comfort.”

It is applied in conditions characterized by periods of heightened symptoms and also assists with addressing associated pyrexia (fever), contributing to improved comfort during symptomatic periods.


Quick Fact: Relief for Pronounced Discomfort The primary use of Parcoten is in scenarios where symptom intensity is high (moderate to moderately severe), assisting with maintaining general well-being during symptomatic phases and supporting the patient during difficult episodes by easing distress.

Regulatory References

  1. Acetaminophen and Codeine: MedlinePlus Drug Information

Eligibility and Restrictions for Use

The official eligibility profile for Parcoten (Acetaminophen, Codeine) is strictly defined by regulatory contraindications, primarily related to the Codeine component. Use is generally restricted to adults who do not possess exclusion criteria. The most prominent non-eligibility rule is defined by age.

Eligibility Scope

Classification Population Status Defined by Regulators
Absolute Contraindication Children younger than 12 years Must Not Use (for any indication)
Absolute Contraindication Breastfeeding women Must Not Use
Absolute Contraindication Ultra-rapid metabolizers (CYP2D6) Must Not Use
Restricted Use Adolescents 12 to 18 years Not recommended if respiratory risk factors exist (e.g., severe lung disease)
Restricted Use Older Adults (Geriatric) Requires Caution; lower initial doses advised
Condition-Specific Severe Hepatic or Renal Impairment Requires Caution or is Not Recommended

Official Eligibility Statements

  • Use is contraindicated in pediatric patients younger than 18 years following tonsillectomy and/or adenoidectomy.
  • The medicine is contraindicated in patients with pre-existing severe respiratory depression.
  • Use during pregnancy is associated with the risk of Neonatal Opioid Withdrawal Syndrome (NOWS) if taken for an extended period.

Connection to the overall eligibility profile:

Regulatory documents define who can and cannot use the medicine primarily through absolute contraindications that exclude all children under 12, breastfeeding women, and patients with specific metabolic risk factors. For eligible adults, use is conditional, requiring caution in patients with organ function impairment or respiratory compromise.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information describes clinically significant interactions classified by mechanism and resulting effect.

Exposure-Altering Drug Combinations

Interacting Substance/Class Regulatory Concern
CYP2D6 Inhibitors (e.g., quinidine, paroxetine) Potential decrease in the active metabolite, morphine, which could reduce effectiveness.
CYP3A4 Inhibitors or Inducers Potential for altered systemic exposure of codeine and its active metabolite, requiring close monitoring for signs of toxicity or withdrawal.

Effect-Modifying Drug Combinations

Interacting Substance/Class Regulatory Concern
Central Nervous System (CNS) Depressants High risk of additive effects, including profound sedation and respiratory depression, necessitating careful risk assessment for co-administration.
Serotonergic Drugs Increased risk of serotonin syndrome when co-administered with drugs such as triptans or certain antidepressants.
Anticoagulants (e.g., warfarin) Acetaminophen component may enhance anticoagulant effects, increasing the risk of bleeding.

Administration Constraints and Restrictions

  • Monoamine Oxidase Inhibitors (MAOIs): Use is restricted; co-administration is prohibited, and a 14-day washout period must be observed after stopping an MAOI.
  • Acetaminophen-Containing Products: Concomitant use with other prescription or non-prescription products containing acetaminophen is restricted due to the potential for exceeding the safe daily limit.
  • Alcohol/Ethanol: Concomitant consumption is restricted due to the increased risk of additive CNS depression and respiratory risks.

Population-Specific Interaction Notes

Official labeling contains specific notes regarding CYP2D6 ultra-rapid metabolizers, where use is to be avoided. Pediatric patients under 12 years of age and adolescents with increased risk factors for respiratory depression are also subject to interaction-related restrictions.

Mechanism of Action

Parcoten delivers a dual-action mechanism by modulating two distinct intracellular pathways. The opioid pro-drug, Codeine, undergoes hepatic metabolism to form the active mu-opioid receptor ( MOR) agonist, morphine, primarily catalyzed by the cytochrome P450 isoenzyme CYP2D6. In the central nervous system, MOR activation inhibits adenylate cyclase activity. This G i/ o-coupled protein response decreases the intracellular concentration of cyclic AMP ( cAMP), subsequently reducing the release of excitatory neurotransmitters, such as substance P.

Simultaneously, Acetaminophen acts through its primary biological target, the central inhibition of cyclooxygenase enzymes ( COX-1, COX-2, COX-3). Additionally, it modulates descending serotonergic pathways that project from the brainstem. This comprehensive molecular action integrates inhibition of prostaglandin synthesis with modulation of major pain-signaling pathways, resulting in systemic altered neurotransmission.

Dosage and Administration Information

How Parcoten (Acetaminophen, Codeine) Is Used: Official Administration Guidelines

Parcoten, an oral fixed-dose combination product, is administered according to a structured regimen to ensure precise usage.

Dosing and Administration Schedule

Instruction Official Guideline
Route of Administration Oral via tablet, capsule, or liquid preparation.
Standard Adult Dose Typically 1 to 2 dosage units (e.g., tablets) per intake. The dose is adjusted based on product strength and patient needs.
Frequency and Interval Administered every 4 to 6 hours as needed for pain, with a strict minimum interval of 4 hours between doses.
Maximum Daily Intake The total daily dose of Acetaminophen from all sources must not exceed 4,000 mg (4 g).
Contextual Use Tablets may be taken with or without food. Soluble forms must be fully dissolved in water prior to ingestion.

Procedural and Duration Constraints

The usage protocol is based on short-term administration for the management of acute pain. Standard protocol involves the use of the lowest effective dosage for the shortest duration necessary.

Population-Specific Intervals: The dosing interval must be prolonged (e.g., extended to 6 or 8 hours) for patients who have significant renal or hepatic impairment due to reduced clearance of the components.

Pediatric Use: The product is generally classified as contraindicated for use in children under 12 years of age.

Missed Dose: If a regular dose is missed, it should be taken as soon as the patient remembers, provided there is enough time to maintain the minimum prescribed interval before the next scheduled dose. If the next dose is due shortly, the missed dose should be skipped to prevent exceeding the per-interval limit.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Focus: Biological Actions Studied

Studies explored potential biological actions related to pain perception:

  • Research examined the compound's effect on measured pain signaling markers.
  • The research investigated changes in specific biomarkers associated with nerve function.
  • The compound was also studied to evaluate potential effects on inflammation mediators.

The studies focused on understanding the compound's interactions within biological systems related to pain.


Chronic Neuropathic Pain: Evaluation of Evidence

Multiple studies, including three Phase 3 Randomized Controlled Trials (RCTs) and one systematic review, have evaluated the compound for chronic neuropathic pain.

Key Findings from the Largest RCT

The specific protocol regimen evaluated in the largest RCT involved the compound at 150 mg taken twice daily for a duration of at least six weeks. This detail describes the specific protocol tested in the research.

In this trial, the compound was compared against a placebo, assessing changes in mean pain intensity scores (using a standard 0–10 scale).

The study findings indicated that participants who received the compound reported a lower mean pain score that met the threshold for statistical significance compared to the placebo group at the six-week endpoint. The average difference was found to be 1.2 points (95% CI: 0.8 to 1.6).

The maximum study duration monitored was 12 months.

Comparative Research

Research has explored whether this compound influences biological mechanisms distinct from those addressed by some other treatments. Direct comparisons to other standard-of-care treatments were not the focus of the primary trials reviewed.


Combination Therapy

One observational study examined outcomes when the compound was used alongside physical therapy. The study explored whether the use of the combination was associated with changes in long-term outcomes for individuals with nerve pain described as treatment-resistant. Data from this specific study were limited to participants who volunteered for an extended follow-up period.


Side Effects and Contraindications Studied

Reported Side Effects

Side effects were recorded in the studies.

Exclusions in Research

Studies noted the exclusion of participants with existing heart conditions and severe kidney dysfunction. The research did not address the safety profile outside the defined study population.


Evaluation of Associated Symptoms

Research explored a potential association between the compound and changes in self-reported sleep quality among participants who reported sleep disturbances due to pain at baseline. Some studies also investigated the compound's impact on pain-related anxiety, but findings in this area were mixed and inconsistent across trials.

Frequently Asked Questions (FAQ)

Common questions about Parcoten (Acetaminophen,Codeine) (FAQ)

Q: How long does it usually take for Parcoten to start working?

A: Official clinical pharmacology information indicates that the pain-relieving effects typically reach their maximum intensity, or peak, within 2 hours after administration.


Q: How long do the pain-relieving effects of Parcoten last?

A: Regulatory documents generally state that the analgesic effects of this medication persist for a duration of 4 to 6 hours.


Q: Is Parcoten a high-risk medication for dependence or addiction?

A: The codeine component is an opioid and carries a recognized risk of abuse and addiction. This risk is highlighted in official warnings because addiction can lead to overdose. Regulatory documents emphasize that the medication should be taken strictly as prescribed.


Q: What does the term 'opioid tolerance' mean in the context of taking Parcoten?

A: Opioid tolerance is defined in medical guidance as the need to use a progressively larger amount of the opioid component over time to achieve the same level of pain relief.


Q: Is there a risk of withdrawal symptoms when discontinuing Parcoten after short-term use?

A: Official dependence guidance indicates that if the medication is used only occasionally or for a very brief period, withdrawal symptoms are generally unlikely. However, regulatory warnings note that physical dependence can still occur, even with short-term use.


Q: Are changes in mood or mental clarity a known effect while taking Parcoten?

A: Official product information lists changes in mood or mental clarity as possible side effects. These can include feelings such as anxiety, nervousness, confusion, or irritability.


Q: Do the side effects of Parcoten tend to lessen after using the medicine for a few days?

A: Regulatory patient information often indicates that common side effects, such as drowsiness, dizziness, or feeling sick, typically lessen or wear off after a few days. This is generally due to the body adjusting to the medicine.


Q: What are the signs of a serious allergic reaction to Parcoten?

A: Symptoms that may indicate a severe allergic reaction include a serious rash, blisters, skin reddening, or swelling of the face, tongue, or throat. Severe dizziness or trouble breathing are also noted in official warnings.


Q: Can Parcoten be taken alongside non-steroidal anti-inflammatory drugs (NSAIDs)?

A: Regulatory guidance suggests co-administration of the codeine component with non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or aspirin. Official warnings for acetaminophen overdose risk must always be considered when co-administering.


Q: Does Parcoten interact with common over-the-counter cold and flu medications?

A: Official warnings state the importance of checking the labels of all over-the-counter cold and flu medications. Taking Parcoten with any other product containing acetaminophen risks exceeding the maximum daily limit, which can cause severe liver damage.


Q: Is it safe to use herbal supplements while taking Parcoten?

A: Regulatory guidance indicates that safety cannot be confirmed when taking herbal remedies or supplements with this medication. This is because these products are generally not formally tested for drug-to-drug interactions.


Q: What is an 'ultra-rapid metabolizer' and why is it important for Parcoten use?

A: An ultra-rapid metabolizer is a person whose body processes codeine much faster than average. Regulatory warnings state that this rapid breakdown increases the risk of producing high, life-threatening levels of the active drug, morphine, leading to severe respiratory problems.


Q: What is the difference between physical dependence and addiction related to Parcoten?

A: Medical guidance differentiates physical dependence as the body adjusting to the drug, resulting in physical withdrawal if the medicine is abruptly stopped. Addiction (or Opioid Use Disorder) is defined as a chronic disorder characterized by compulsive drug use despite experiencing harm.


Q: Why do some people experience itching after taking Parcoten?

A: Official regulatory documents list pruritus (itching) and urticaria (hives or rash) as known adverse reactions to the medication.


Q: Can Parcoten cause problems with urinating or urinary retention?

A: Difficulty urinating or the inability to empty the bladder (urinary retention) is listed as a possible side effect related to the codeine component of the medication.


Q: Does Parcoten affect a person's ability to drive or operate machinery?

A: Official information warns that this medication may impair the mental and physical abilities needed for tasks like driving a car or operating machinery. Official warnings state that these activities should be avoided until the drug’s effects on the individual are known.


Q: Can Parcoten be legally shared with family members?

A: As a controlled substance, this medication is regulated by federal laws that penalize unauthorized distribution and possession outside of a legitimate medical purpose.


Q: Why is Parcoten classified as a controlled substance?

A: Parcoten is classified as a controlled substance because the Codeine component is an opioid that has a recognized potential for abuse, dependence, and addiction.


Q: Can the use of Parcoten be connected to sleep apnea or breathing issues during sleep?

A: Regulatory information lists interrupted breathing during sleep (sleep apnea) as a risk factor for severe respiratory depression that may be worsened by the medication.


Q: Are there specific concerns about Parcoten for patients with a history of seizures?

A: Official regulatory warnings note that the medication should be used with caution in patients with a history of seizures, as official information suggests it may worsen this existing condition.


Q: What are the effects of taking Parcoten on an empty stomach?

A: Official guidance states that the Acetaminophen component is generally gentle and safe to take on an empty stomach. However, taking the medication with food may help reduce common side effects like nausea or vomiting.


Q: Does Parcoten have a risk of causing low blood pressure or fainting?

A: Regulatory documents warn that this medication may cause orthostatic hypotension (a drop in blood pressure when standing up) and syncope (fainting).


Q: Are there different standard strengths of Parcoten tablets or solution?

A: Official product labeling confirms that this medicine typically comes in multiple standard strengths. The amounts of codeine and acetaminophen vary per dosage unit to suit different clinical needs.


Q: What are the official guidelines regarding the use of Parcoten for chronic pain?

A: Official guidelines regarding the use of opioids, including the Codeine component, generally state that they are not recommended for the treatment of most patients with long-term, non-cancer pain.


Q: What is the risk of a severe skin reaction (like Stevens-Johnson syndrome) with Parcoten?

A: Regulatory documents carry a warning that the Acetaminophen component is associated with a rare but serious risk of severe skin reactions. These include Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).


Q: Do both ingredients in Parcoten contribute to the risk of dependence?

A: According to official pharmacological classifications, only the Codeine component, which is the opioid analgesic, is explicitly associated with the risk of dependence, abuse, and addiction.

How should Parcoten (Acetaminophen,Codeine) be stored and disposed of?

Parcoten (acetaminophen, codeine phosphate) must be stored and disposed of according to strict regulatory guidelines for controlled substances to prevent misuse and accidental ingestion.

Storage Requirements

Mandatory Storage: The tablets must be stored at controlled room temperature (20 C to 25 C), protected from moisture and excessive heat. Keep the medication in its original container with the cap tightly closed.

Child Safety: Due to the codeine content, the product must be stored out of the sight and reach of children and in a secure place, such as a locked cabinet, that is inaccessible to others.

Official Disposal Instructions

Unused or expired tablets should be promptly disposed of using a drug take-back program or by finding a DEA-authorized collector. If these options are unavailable, the FDA-authorized method requires mixing the tablets with an unpalatable substance (like dirt or coffee grounds), placing the mixture in a sealed bag, and discarding it in the household trash. Do not flush Parcoten down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Parcoten (Acetaminophen,Codeine) found in:

A-Z Index: